Navigation Links
Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
Date:7/31/2009

CARLSBAD, Calif., July 31 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of skin scarring and fibrotic disorders, is pleased to announce that Jay Birnbaum, Ph.D. has joined the Board of Directors as an Independent Board Member.

Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, medical devices, and cosmeceuticals. His 35 years of industry experience span the areas of discovery research, formulations, clinical R&D, regulatory and marketing, and he has been involved in the development and commercialization of numerous drug and consumer products and brands. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals, a company developing products in aesthetic dermatology. Prior to starting his own consulting company in 1999, he was with Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President, Global Project Management, with responsibilities for strategic planning and development of the company's dermatology portfolio. Prior to that, Dr. Birnbaum held various management positions at the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth).

Dr. Birnbaum has broad relationships in industry and academia, and has published extensively on his work in drug development. His professional affiliations include the American Academy of Dermatology, Society of Investigative Dermatology, European Academy of Dermatology and Venereology, American Society for Dermatologic Surgery, and International Society of Dermatology. He is a member of the board of directors of Oculus Innovative Sciences, Inc. and is on the Science Advisory Boards of Evolva, NanoBio Corp, NexMed, Inc., Topica Pharmaceuticals, and Transport Pharmaceuticals.

He received a B.S. degree from Trinity College and a Ph.D in Pharmacology from the University of Wisconsin.

Excaliard Pharmaceuticals, Inc,(R) is delighted to have an individual with Jay's technical and business experience join the Board of Directors and looks forward to his many contributions.


'/>"/>
SOURCE Excaliard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
2. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
4. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
5. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
7. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
9. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
10. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
11. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... ... questioned the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) ... is a minimally invasive procedure performed, when indicated, to correct the partial ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... , ... Coast Dental Fort Stewart is celebrating its grand opening with an ... Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, ... have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
Breaking Medicine Technology: